Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst BIomarkers Detection (INCITE) Consortium

Launched by IRCCS SAN RAFFAELE · Nov 15, 2024

Keywords

ClinConnect Summary

The INCITE trial is focused on improving how we identify invasive intraductal papillary mucinous neoplasms (IPMNs), which are growths in the pancreas that could lead to pancreatic cancer. Researchers are looking for new markers—like genetic and lifestyle factors—that can help tell if these growths are dangerous. This is important because some patients with benign (non-cancerous) IPMNs may be treated too aggressively, leading to unnecessary surgeries and complications. By studying samples from patients, the trial aims to develop a more personalized approach to treatment that could help doctors make better decisions about patient care.

To participate, you need to be an adult over 18 years old with a diagnosed IPMN, whether or not you are planning to have surgery. You will need to provide consent to participate and allow researchers to use your samples. The study will analyze samples from about 800 patients, both from previous studies and new volunteers, to find and validate these important biomarkers. Participants can expect to contribute to significant research that may improve future care for people with IPMNs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (age \>18 years) patients with a diagnosis of IPMN undergoing and not undergoing surgery
• • All patients will sign the informed consent
• For the retrospective patients:
• • confirmed IPMN diagnosis
• • signed informed consent for samples biobanking and study participation
• Exclusion Criteria:
• • Patients \< 18 years of age
• • Patients who are not able to supply an informed consent